Subscribe: pubmed: Eur J Hem[jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0rmp-ilgffswpASPNHcEa4stRoF-4Pw81Cv5l8E75TL
Preview: pubmed: Eur J Hem[jour]

pubmed: Eur J Hem[jour]



NCBI: db=pubmed; Term="European Journal of Haematology"[jour]



 



The presentation and management of platelet disorders in pregnancy.
Related Articles

The presentation and management of platelet disorders in pregnancy.

Eur J Haematol. 2018 Feb 21;:

Authors: Goldman BG, Hehir MP, Yambasu S, O'Donnell EM

Abstract
Thrombocytopenia, defined as a platelet count less than 150,000 per microlitre, occurs in 7-12% of all pregnancies. Aside from anaemia, it is the most common haematological disorder in pregnancy. Despite its frequent occurrence, thrombocytopenia often leads to difficulties of diagnosis and management in pregnancy. Typically, a pregnant woman will have platelet counts of 150,000 to 450,000 per microlitre and platelet counts may be slightly lower than those of healthy, non-pregnant controls. Approximately 8% of pregnant women will develop mild thrombocytopenia (100,000-150,000 per microlitre) and while 65% of these women will have no underlying pathology, all pregnant women with platelet counts of less than 100,000 per microlitre should undergo further clinical and laboratory assessment. Thrombocytopenia in pregnancy occurs as a result of multiple distinct conditions, we present four cases of thrombocytopenia in pregnancy encountered in our unit over a 12 month period. These include gestational thrombocytopenia, immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP) and thrombocytopenia absent radius (TAR) syndrome. The literature review of these cases highlights the significance of identification, understanding pathophysiology and a multidisciplinary approach to these conditions. We refresh knowledge on these conditions and emphasise the importance of thrombocytopenia in pregnancy. This article is protected by copyright. All rights reserved.

PMID: 29464836 [PubMed - as supplied by publisher]




Associations between Fatigue, Physical Activity, and QoL in Patients with Myeloproliferative Neoplasms.
Related Articles

Associations between Fatigue, Physical Activity, and QoL in Patients with Myeloproliferative Neoplasms.

Eur J Haematol. 2018 Feb 21;:

Authors: Tolstrup Larsen R, Tang LH, Brochmann N, Meulengracht Flachs E, Illemann Christensen A, Hasselbalch HC, Zwisler AD

Abstract
BACKGROUND: Patients with Philadelphia-chromosome negative Myeloproliferative Neoplasms (MPNs) report fatigue as the most common symptom and contributing significantly to reduction in their Quality of Life (QoL). Targeted non-pharmacological intervention to increase levels of physical activity is suggested as a fatigue-reducing and QoL-enhancing intervention in MPN patients. The interrelationship between physical activity, fatigue, and QoL have, to our knowledge, never been reported.
METHODS: We analyzed data from 1,807 MPN patients. The primary analysis included a multiple regression model allowing fatigue to mediate the relationship between physical activity and QoL.
RESULTS: We herein report the first and the largest study of patients with MPNs, in whom we have investigated the interrelationship between fatigue, physical activity, and QoL. Sedentary patients were more likely to report fatigue compared to highly active patients. There was a negative association between fatigue and QoL and there was a positive association between physical activity and QoL. There was no interaction between fatigue and physical activity in the association with QoL.
CONCLUSION: We found positive associations between level of physical activity and QoL, independently of fatigue being present. More research is needed before physical activity can be introduced as a targeted intervention to reduce fatigue and increase QoL in the management of patients. This article is protected by copyright. All rights reserved.

PMID: 29464777 [PubMed - as supplied by publisher]